Simulations Plus' (NASDAQ:SLP) Returns On Capital Not Reflecting Well On The Business
Simulations Plus (NASDAQ:SLP): Promising Potential in Biotech Software
Simulations Plus (SLP) DILIsym Software Licenses Renewed by FDA
Simulations Plus (SLP) DILIsym Software Licenses Renewed by FDA
Earnings Update: Simulations Plus, Inc. Beat Earnings And Now Analysts Have New Forecasts For This Year
Simulations Plus Second Quarter 2024 Earnings: Beats Expectations
Simulations Plus, Inc. (NASDAQ:SLP) Q2 2024 Earnings Call Transcript
U.S. FDA Renews DILIsym® Software Licenses for 7th Year
Simulations Plus (SLP) Q2 Earnings & Revenues Beat Estimates
Simulations Plus (SLP) Q2 Earnings & Revenues Beat Estimates
Q2 2024 Simulations Plus Inc Earnings Call
Simulations Plus Inc (SLP) Aligns with EPS Projections and Maintains Full-Year Guidance
Simulations Plus (SLP) Q2 Earnings and Revenues Surpass Estimates
Simulations Plus (SLP) Q2 Earnings and Revenues Surpass Estimates
Simulations Plus Reports Second Quarter Fiscal 2024 Financial Results
Simulations Plus (SLP) to Report Q2 Earnings: What's in Store?
Simulations Plus (SLP) to Report Q2 Earnings: What's in Store?
Craig-Hallum Remains a Buy on Simulations Plus (SLP)
Simulations Plus Announces Second Quarter Fiscal Year 2024 Earnings and Conference Call Date
Adobe Systems (ADBE) Tops Q1 Earnings and Revenue Estimates
•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.•
in mil. unless spec.